In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Black Diamond Therapeutics Inc (NASDAQ: BDTX) was $1.60 for the day, up 0.63% from the previous closing price of $1.59. In other words, the price has increased by $0.63 from its previous closing price. On the day, 0.66 million shares were traded. BDTX stock price reached its highest trading level at $1.64 during the session, while it also had its lowest trading level at $1.565.
Ratios:
Our analysis of BDTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.92 and its Current Ratio is at 4.92. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 31, 2024, initiated with a Outperform rating and assigned the stock a target price of $20.
Stifel Upgraded its Hold to Buy on June 30, 2023, whereas the target price for the stock was revised from $2 to $10.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 19 ’25 when BIOTECH GROWTH N V sold 5,784,292 shares for $2.07 per share. The transaction valued at 11,997,749 led to the insider holds 2,733,547 shares of the business.
Versant Venture Capital VI, L. sold 221,600 shares of BDTX for $1,400,556 on Aug 28 ’24. The 10% Owner now owns 3,726,341 shares after completing the transaction at $6.32 per share. On Jul 31 ’24, another insider, David Epstein, who serves as the Former Employer of the company, bought 50,000 shares for $6.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BDTX now has a Market Capitalization of 91823360 and an Enterprise Value of 14270555.
Stock Price History:
The Beta on a monthly basis for BDTX is 2.64, which has changed by -0.71274686 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, BDTX has reached a high of $7.66, while it has fallen to a 52-week low of $1.20. The 50-Day Moving Average of the stock is -6.94%, while the 200-Day Moving Average is calculated to be -50.99%.
Shares Statistics:
BDTX traded an average of 3.17M shares per day over the past three months and 672450 shares per day over the past ten days. A total of 56.64M shares are outstanding, with a floating share count of 43.15M. Insiders hold about 23.86% of the company’s shares, while institutions hold 64.81% stake in the company. Shares short for BDTX as of 1744675200 were 9635071 with a Short Ratio of 3.04, compared to 1741910400 on 7164034. Therefore, it implies a Short% of Shares Outstanding of 9635071 and a Short% of Float of 24.46.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Black Diamond Therapeutics Inc (BDTX) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $-0.25, with high estimates of $-0.15 and low estimates of $-0.33.
Analysts are recommending an EPS of between $0.23 and $-1.32 for the fiscal current year, implying an average EPS of $-0.41. EPS for the following year is $-0.82, with 3.0 analysts recommending between $-0.74 and $-0.9.
